Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
27.88
+0.15 (0.54%)
Mar 2, 2026, 3:18 PM EST - Market open
Immunovant Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Immunovant stock have an average target of 30.78, with a low estimate of 17 and a high estimate of 50. The average target predicts an increase of 10.40% from the current stock price of 27.88.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Immunovant stock from 9 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 4 | 2 | 2 | 2 | 2 | 2 |
| Hold | 3 | 4 | 4 | 5 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 9 | 9 | 10 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $35 | Strong Buy | Reiterates | $35 | +25.54% | Feb 10, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $41 → $44 | Strong Buy | Maintains | $41 → $44 | +57.82% | Feb 9, 2026 |
| Truist Securities | Truist Securities | Hold Maintains $16 → $22 | Hold | Maintains | $16 → $22 | -21.09% | Jan 8, 2026 |
| Wolfe Research | Wolfe Research | Hold → Buy Upgrades $50 | Hold → Buy | Upgrades | $50 | +79.34% | Jan 6, 2026 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $18 → $28 | Hold | Maintains | $18 → $28 | +0.43% | Dec 15, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
9.79M
EPS This Year
-2.97
from -2.73
EPS Next Year
-3.00
from -2.97
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | n/a | 90.7M | ||||
| Avg | n/a | 9.8M | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | -2.67 | -2.06 | ||||
| Avg | -2.97 | -3.00 | ||||
| Low | -3.15 | -3.87 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.